Jing Huang

Summary

Country: China

Publications

  1. doi request reprint A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College CAMS and PUMC, Beijing 100021, China
    Med Oncol 30:343. 2013
  2. doi request reprint Primary small cell carcinoma of the stomach: an experience of two decades (1990-2011) in a Chinese cancer institute
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College CAMS and PUMC, Beijing, China
    J Surg Oncol 106:994-8. 2012
  3. ncbi request reprint [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus]
    Jing Huang
    Department of Medical Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, P R China
    Zhonghua Zhong Liu Za Zhi 26:753-5. 2004
  4. doi request reprint [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]
    Yi Zhou
    Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing, China
    Zhonghua Zhong Liu Za Zhi 34:860-4. 2012
  5. ncbi request reprint [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]
    Yan Song
    Department of Medical Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People s Republic of China
    Chin J Cancer 29:76-81. 2010
  6. ncbi request reprint Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Chin Med J (Engl) 124:4012-7. 2011
  7. ncbi request reprint A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
    Lin Yang
    Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing 100021, China Email
    Chin Med J (Engl) 126:3470-4. 2013
  8. ncbi request reprint [Long-term results of multimodality therapy of testicular germ cell tumor]
    Jin wan Wang
    Department of Medical Oncology, Cancer Institute Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 25:382-5. 2003
  9. ncbi request reprint [Responses of advanced esophageal cancer to chemotherapy and prognostic factors: a report of 138 cases]
    Ai Na Liu
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, PR China
    Ai Zheng 27:400-6. 2008
  10. ncbi request reprint [Inflammatory breast cancer: 38 cases clinical report]
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, P R China
    Ai Zheng 21:888-91. 2002

Collaborators

Detail Information

Publications10

  1. doi request reprint A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College CAMS and PUMC, Beijing 100021, China
    Med Oncol 30:343. 2013
    ..Our study indicates that the expression of ERCC1 evaluated by immunohistochemistry is a promising predictive marker for response in patients with metastatic ESCC receiving cisplatin-paclitaxel regimen...
  2. doi request reprint Primary small cell carcinoma of the stomach: an experience of two decades (1990-2011) in a Chinese cancer institute
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College CAMS and PUMC, Beijing, China
    J Surg Oncol 106:994-8. 2012
    ..Primary gastric small cell carcinoma (GSCC) is a rare and aggressive disease for which the standard treatment has not been established. The objective of this study is to investigate the clinical characteristics and survival...
  3. ncbi request reprint [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus]
    Jing Huang
    Department of Medical Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, P R China
    Zhonghua Zhong Liu Za Zhi 26:753-5. 2004
    ..Paclitaxel was used in a phase II trial in combination with cisplatin for esophageal cancer. The anti-tumor response, toxicity and survival of the treated patients were evaluated...
  4. doi request reprint [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]
    Yi Zhou
    Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing, China
    Zhonghua Zhong Liu Za Zhi 34:860-4. 2012
    ..The purpose of this study was to analyze the safety and compliance of this combination regimen as adjuvant chemotherapy in patients with gastric cancer...
  5. ncbi request reprint [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]
    Yan Song
    Department of Medical Oncology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People s Republic of China
    Chin J Cancer 29:76-81. 2010
    ..This study was to investigate the relationship between the expression of HER2/neu and the clinical characteristics of advanced gastric carcinomas, including survival...
  6. ncbi request reprint Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Chin Med J (Engl) 124:4012-7. 2011
    ..Prior studies had demonstrated potential synergistic antitumor activity of gemcitabine in combination with cisplatin. Therefore, we studied the efficacy and tolerability of such combination for esophageal cancer...
  7. ncbi request reprint A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer
    Lin Yang
    Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing 100021, China Email
    Chin Med J (Engl) 126:3470-4. 2013
    ..We conducted a Phase II trial to determine the efficacy and safety of S-1 plus oxaliplatin (SOX regimen) as first-line chemotherapy for patients with unresectable locally advanced or metastatic gastric cancer...
  8. ncbi request reprint [Long-term results of multimodality therapy of testicular germ cell tumor]
    Jin wan Wang
    Department of Medical Oncology, Cancer Institute Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 25:382-5. 2003
    ..To study the clinical characteristics, outcome, prognostic factors and survival of patients with testicular germ cell tumors (TGCTs)...
  9. ncbi request reprint [Responses of advanced esophageal cancer to chemotherapy and prognostic factors: a report of 138 cases]
    Ai Na Liu
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, PR China
    Ai Zheng 27:400-6. 2008
    ..There are no definite prognostic factors and standard regimens for these patients. This study was to analyze the responses of advanced esophageal cancer to chemotherapy, and explore its probable prognostic factors...
  10. ncbi request reprint [Inflammatory breast cancer: 38 cases clinical report]
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, P R China
    Ai Zheng 21:888-91. 2002
    ..Inflammatory breast cancer (IBC) is a special form of rapidly progressive breast cancer with poor prognosis. The purpose of this study was to investigate the clinical characters, treatment, and prognosis of inflammatory breast cancer...